inspequte
[!WARNING] Experimental / Proof-of-Concept Project
This repository is intended for experimental and evaluation purposes only. It is not designed, reviewed, or supported for production use.
Do NOT use this code in production environments.
inspequte is a fast, CLI-first static analysis tool for JVM class and JAR files. It focuses on CI/CD speed, deterministic output, and SARIF-only reporting for global standard compatibility.
The name combines "inspect" and "qute". The CLI command is inspequte.
Goals
- Fast startup and analysis for CI pipelines.
- No IDE or build-tool integration required.
- Deterministic SARIF v2.1.0 output for LLM-friendly automation.
Bytecode/JDK compatibility
- Supports JVM class files up to Java 21 (major version 65).
- Requires a Java 21 toolchain when compiling test harness sources via
JAVA_HOME. - Some advanced bytecode attributes may still be skipped in future releases.
CLI usage
inspequte --input app.jar --classpath lib/ --output results.sarif
Create a baseline of current findings to suppress them in future runs:
inspequte baseline --input app.jar --classpath lib/ --output inspequte.baseline.json
Run with a baseline to emit only new issues:
inspequte --input app.jar --classpath lib/ --output results.sarif --baseline inspequte.baseline.json
If you omit --baseline output/input paths, .inspequte/baseline.json is used by default; missing files are ignored.
SARIF output (example)
CI integration (GitHub Actions)
- name: Install inspequte
run: cargo install inspequte --locked
- name: Run inspequte
run: |
inspequte \
--input app.jar \
--classpath lib/ \
--output results.sarif
Upload SARIF to GitHub Code Scanning
- name: Upload SARIF
uses: github/codeql-action/upload-sarif@v3
with:
sarif_file: results.sarif
Validate SARIF during CI (optional)
- name: Run inspequte with schema validation
run: |
INSPEQUTE_VALIDATE_SARIF=1 inspequte \
--input app.jar \
--classpath lib/ \
--output results.sarif
License
AGPL-3.0. See LICENSE.
Contributing
Please follow Conventional Commits 1.0.0. See CONTRIBUTING.md.